Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials

Bibliographic Details
Title: Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
Authors: Vincent Madelain, France Mentré, Sylvain Baize, Xavier Anglaret, Cédric Laouénan, Lisa Oestereich, Thi Huyen Tram Nguyen, Denis Malvy, Géraldine Piorkowski, Frederik Graw, Stephan Günther, Hervé Raoul, Xavier deLamballerie, Jérémie Guedj
Source: CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 5, Pp 258-271 (2020)
Publisher Information: Wiley, 2020.
Publication Year: 2020
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: Therapeutics. Pharmacology, RM1-950
More Details: In 2014, our research network was involved in the evaluation of favipiravir, an anti‐influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2163-8306
Relation: https://doaj.org/toc/2163-8306
DOI: 10.1002/psp4.12510
Access URL: https://doaj.org/article/c3eb6c0c096749a2a43547dd624cdc4d
Accession Number: edsdoj.3eb6c0c096749a2a43547dd624cdc4d
Database: Directory of Open Access Journals
More Details
ISSN:21638306
DOI:10.1002/psp4.12510
Published in:CPT: Pharmacometrics & Systems Pharmacology
Language:English